Search Results - "Ferrari, Renda H."

Ixazomib for the treatment of multiple myeloma by Richardson, Paul G, Zweegman, Sonja, O'Donnell, Elizabeth K, Laubach, Jacob P, Raje, Noopur, Voorhees, Peter, Ferrari, Renda H, Skacel, Tomas, Kumar, Shaji K, Lonial, Sagar

“…Proteasome inhibitors (PIs) are among the backbones of multiple myeloma (MM) treatment; however, their long-term use can be limited by parenteral…”
Get more information

Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib by Manda, Sudhir, Yimer, Habte A., Noga, Stephen J., Girnius, Saulius, Yasenchak, Christopher A., Charu, Veena, Lyons, Roger, Aiello, Jack, Bogard, Kimberly, Ferrari, Renda H., Cherepanov, Dasha, Demers, Brittany, Lu, Vickie, Whidden, Presley, Kambhampati, Suman, Birhiray, Ruemu E., Jhangiani, Haresh S., Boccia, Ralph, Rifkin, Robert M.

“…The ongoing US MM-6 study is investigating in-class transition (iCT) from parenteral bortezomib-based induction to all-oral IRd…”
Get full text

Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients by Thompson, Michael A., Boccadoro, Mario, Leleu, Xavier, Vela-Ojeda, Jorge, van Rhee, Frits, Weisel, Katja C., Rifkin, Robert M., Usmani, Saad Z., Hájek, Roman, Cook, Gordon, Abonour, Rafat, Armour, Mira, Morgan, Kathryn E., Yeh, Su-Peng, Costello, Caitlin L., Berdeja, Jesus G., Davies, Faith E., Zonder, Jeffrey A., Lee, Hans C., Omel, Jim, Spencer, Andrew, Terpos, Evangelos, Hungria, Vania T.M., Puig, Noemi, Fu, Chengcheng, Ferrari, Renda H., Ren, Kaili, Stull, Dawn Marie, Chari, Ajai

“…[Display omitted] •Pneumococcal- and influenza vaccination (PV; FV) are recommended forMultiple Myeloma(MM) patients.•However, data on vaccination status and…”
Get full text

Multiple myeloma (MM) vaccination (influenza, FV and pneumococcal, PV) rates worldwide and impact on infection, hospitalization, and death by Thompson, Michael A., Costello, Caitlin, Berdeja, Jesus G., Davies, Faith, Zonder, Jeffrey A., Lee, Hans Chulhee, Omel, Jim, Spencer, Andrew, Terpos, Evangelos, Hungria, Vania, Puig, Noemi, Fu, Cheng-Cheng, Skacel, Tomas, Ferrari, Renda H., Ren, Kaili, Stull, Dawn Marie, Chari, Ajai

“…Abstract only 8528 Background: MM is a cancer of the immune system. Infections are common reasons for hospitalization and death in MM. As MM patients (pts) are…”
Get full text

Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: Analysis of over 3,000 Pts from the Insight MM Global, Prospective, Observational Study by Hungria, Vania T.M., Lee, Hans C., Abonour, Rafat, Rifkin, Robert M., Terpos, Evangelos, Leleu, Xavier, Costello, Caitlin L., van Rhee, Frits, Weisel, Katja C., Puig, Noemi, Berdeja, Jesus G., Cook, Gordon, Usmani, Saad Z., Thompson, Michael A., Boccadoro, Mario, Zonder, Jeffrey A., Spencer, Andrew, Hajek, Roman, Fanning, Suzanne R., Boyd, Kevin, Omel, Jim, Armour, Mira, Morgan, Kathryn E., Patel, Ronak S., Carlson, Gary L., Ferrari, Renda H., Stull, Dawn Marie, Ren, Kaili, Cherepanov, Dasha, Pottala, James V., Chari, Ajai

“…Background Multiple groups of pts, including elderly/frail pts and those with comorbidities, are typically under-represented in randomized controlled trials…”
Get full text